Faecal microbiota transplantation for Clostridium difficile infection a multicentre study of non-respondersRoshan Razik Majdi Osman Alexandra Lieberman Jessica R Allegretti Zain Kassamaecal microbiota transplantation FMT has emerged as an effective therapy for recurrent Clostridium difficile infection rCDI but 10e30 of patients do not respond to treat- ment.Data on this patient phenotype are scarce in this article we describe a cohort of 135 patients in the United States who did notrespond to FMT.We assessed consecutively collected prospective case report forms for patients who did not respond to FMT for rCDI completed by physicians during August 2014 e November 2015 and submitted to a not-for-profit stool bank OpenBiome .Demographic clinical and treatment characteristics were evaluated.

Frozen vs fresh fecal microbiota transplantation and clinical resolution of diarrhea in patients with recurrent Clostridium difficile infection a randomized clinical trial.

Treating Clostridium difficile infection with fecal microbiota transplantation.

Given the broad adoption of FMT guidelines are required for improving education developing criteria for assessing non-response to FMT and guiding the informed consent process so that clear advice about risks benefits and alternatives can be provided including the risk of non-response.Acknowledgements We thank Nancy Dubois OpenBiome and Boston College Boston MA for her technical assistance and the Neil and Anna Rasmussen Family Foundation Concord MAand the Anna Maria and Stephen Kellen Foundation New York City NY for their financial support of OpenBiome.Competing interests Majdi Osman Alexandra Lieberman and Zain Kassam are employed at OpenBiome a not-for-profit stool bank that provides clinicians with preparations for faecal microbiota transplantation and supports research into the human microbiome and its role in medicine.

A high rate of alternative diagnoses in patients referred for presumed Clostridium difficile infection.

